FDA Approves Modeyso as First Treatment for H3 K27M-Mutant Diffuse Midline Glioma
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the US.



We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Google Tag Manager simplifies the management of marketing tags on your website without code changes.